

REMAP-CAP IS SMART

CONTINUOUS OPTIMIZED EFFICIENT

WATCH
NOW

Newsletter Issue #9 | December, 2020

Dear member of the REMAP-CAP family,

In this newsletter we want to give you a heads up on all the exciting new things happening within REMAP-CAP and to provide you with information you cannot miss!

EU total patients randomized

2314

EU COVID-19 patients
randomized

2100

EU non COVID-19 patients
randomized

214

Site and Recruitment Update

In the month November we have welcomed 6 new European sites to the growing family of REMAP-CAP. We are excited about our collaboration and making a difference in the treatment of CAP and COVID-19 patients together:

- Meander Medisch Centrum (the Netherlands),
- Universitätsklinikum Frankfurt (Germany),
- Carl-Thiem-Klinikum Cottbus (Germany),
- Onze Lieve Vrouwe Gasthuis (the Netherlands),
- Haga Ziekenhuis (the Netherlands),
- Beaumont Hospital Dublin (Ireland).

We also want to acknowledge all the great work active sites have put into the trial thus far. We are very proud to announce that REMAP-CAP is currently (9th Dec 2020) active in **281 sites** worldwide and a total of **3,530 unique patients** have been included, of which **2,784 COVID-19** patients. These patients contributed to a total of **6,666 randomizations** in the different domains. Thank you for all the

Publication in JAMA

The results of the REMAP-CAP trial contributed to the scientific evidence on the use of corticosteroids in critically ill patients with COVID-19. On September 2nd REMAP-CAP results were published in JAMA, showing that compared with no hydrocortisone, a 7-day fixed-dose course of hydrocortisone resulted in 93% probability of superiority with regard to odds of improvement in organ support-free days within 21 days.

Check out our webinar in which REMAP-CAP Principal Investigator (PI) for the UK Anthony Gordon, UK Project Manager Farah Al-Beidh, Canadian co-PI Srinivas Murthy and US PI Derek Angus discuss the results with Lennie Derde, European Coordinating Investigator.

If you prefer listening to a podcast, you can find us on Spotify and iTunes (REMAP-CAP) where *Critical Care Reviews'* Director Rob Mac Sweeney talks to REMAP-CAP investigators Derek Angus and Anthony Gordon about the publication.



**REMAP-CAP
PODCAST**

REMAP-CAP IS SMART

CONTINUOUS OPTIMIZED EFFICIENT

WATCH
NOW

Press release

More [encouraging news](#) was announced on November 19th. On the recommendation of the data safety and monitoring board, **REMAP-CAP declared efficacy of Tocilizumab on a combination of survival and length of time patients received organ support in ICU, compared with standard care, compared to no immune modulator.**

This result is based on the first 303 severely ill patients randomized in the COVID19 immune-modulation domain. The data is being analyzed for full release and publication, with database lock planned for December 12th. Relative benefits of tocilizumab, compared with other agents in the immune-modulation domain (sarilumab, interferon-beta-1α, or anakinra) are currently unknown at this point and more data will emerge over the coming months as randomization continues.

A second recommendation was to stop randomization into the lopinavir/ritonavir arm of the COVID-19 Antiviral Domain, as a predefined futility trigger was hit. This means this domain currently holds no active interventions and remains dormant.



If there is an aspect you want to learn or talk about, let us know!

Feel free to contact us directly at eu.remapcap@umcutrecht.nl with any suggestions

We4you Webinars

We4you meetings are organized every other Wednesday at 16.00 CET to keep you up-to-date on different aspects of REMAP-CAP and interact with your fellow investigators. You can watch previous webinars via the links below:

We4You #1: [Background of REMAP-CAP](#)

We4You #2: [Mechanisms of thrombosis in COVID-19](#)

We4You #3: [Therapeutic Targets for COVID-19](#)

We4You #4: [Adaptive Design Features of REMAP-CAP](#)

We4You #5: [COVID-19 Immune Modulation +Antiviral Domain Platform Conclusions](#)

We will kick off the We4you in 2021 on January 6th.

REMAP-CAP on social media

Find us on Twitter (@remap_cap), Instagram (@REMAPCAP) and LinkedIn (REMAP-CAP) where we post results, recruitment updates and more REMAP-CAP news.



For questions contact our PM team at eu.remapcap@umcutrecht.nl